Jaco is Chief Innovation at OMV Petrom, driving their change towards a more innovative and digitally dexterous company with a healthy portfolio of new business options.
Before OMV, he spent four years at Shell, helping their transition to a more Open Innovation approach. He re-invigorated initiatives like GameChanger (radical early stage innovation) and External Technology Coordination, and set up internal networks and learning programs to drive culture change. He built Shell TechWorks, an innovative outfit that maximizes the use of external technologies in a ‘skunkworks’ approach. Jaco also spent 23 years with Royal DSM in progressive roles across four different businesses, including VP Business Incubator and Director of the China Innovation Centre. As member of the DSM Innovation Council, he drove change from operational excellence to innovation excellence.
<p class="x_MsoNormal"><i><span lang="EN-GB">Rhys Evans is the Senior Director of CTS and Global Supply at RxSource where he oversees the Commercial Team and strategic growth of clinical trial services.</span></i></p>
<p class="x_MsoNormal"><i><span lang="EN-GB">Rhys has worked in the clinical trial services arena for over 8 years and has a passion for exploring ways to streamline the supply chain to accelerate patients access to medicines without compromising on quality. Rhys has a PhD in Respiratory Pharmacology and a First-Class Honours Degree in Applied Physiology and Pharmacology.</span></i></p>
<p class="x_MsoNormal"><i><span lang="EN-GB">In addition to working for RxSource, Rhys is a member of the Global Clinical Supplies Group Committee.</span></i></p>
James Clancy – Clinical Operations Lead at Mereo BioPharma. Over 15 years’ experience in clinical operations from early to late phase and wide range of indications. Currently working with rare disease field where the team has recently overseen completion of enrolment in the largest trial undertaken in osteogenesis imperfecta.
As Chief Medical Officer, Dr. Hoffman leads the global medical staff and provides medical oversight and expertise to support early clinical research studies. Dr. Hoffman has over 28 years of knowledge and experience as a physician in the pharmaceutical, device, and CRO industries to this role. He has extensive experience in global drug development, medical affairs, pharmacovigilance and regulatory affairs, and has a proven track record in building, managing and globalizing medical teams. Prior to this role, Dr. Hoffman served as Chief Medical Officer at Patient iP, providing clinical leadership around Patient iP’s innovative platform, customer programs and related medical affairs activities. Dr. Hoffman has also held the roles of Chief Medical Officer and Senior Vice President and General Manager over the Biopharmaceutical Business Unit at Theorem Clinical Research, leading the development of drugs and biologics. Previously in his career, he held positions of increasing responsibility in Medical and Scientific Affairs at Baxter, Hospira and Covance, providing senior-level strategic direction for Phase II-IV programs.
